Literature DB >> 33761547

Hyperbaric oxygen treatment: Results in seven patients with severe bacterial postoperative central nervous system infections and refractory mucormycosis.

Pedro Valente Aguiar1,2,3, Bruno Carvalho1,2, Pedro Monteiro1,2, Paulo Linhares1,2,4, Óscar Camacho5, Rui Vaz1,2,4.   

Abstract

INTRODUCTION: Resistant bacterial infections following brain and spine surgery and spontaneous mucormycosis with central nervous system (CNS) involvement represent a serious treatment challenge and more efficient therapeutic approaches ought to be considered. Hyperbaric oxygen treatment (HBOT) has shown promise as a complementary therapy. This case series evaluated whether HBOT contributed to infection resolution in seven patients with refractory CNS infectious conditions.
METHODS: Clinical results for seven patients referred for HBOT between 2010 to 2018 to treat refractory postoperative brain and spine infections or spontaneously developing mucormycosis were retrospectively analysed. The patients' clinical files and follow-up consultations were reviewed to assess evolution and outcome.
RESULTS: Seven patients were referred with a median age of 56 years. The median follow-up was 20 months. Four patients had postoperative infections and three had rhino-orbital-cerebral mucormycosis (ROCM). HBOT was used as an adjunctive treatment to antimicrobial therapy in all patients. Prior to HBOT, all patients had undergone an average of four operations due to infection refractoriness and had completed an average of five months of antimicrobial therapy. After HBOT, infection resolution was obtained in six patients without additional operations, while one patient with ROCM stopped HBOT after the third session due to intolerance. Three patients stopped antimicrobial therapy while four were maintained on prophylactic treatment.
CONCLUSIONS: Infection resolution was reached in the six patients that completed HBOT as prescribed. HBOT may serve as an effective complementary treatment in CNS refractory postoperative and spontaneous infections. Copyright: This article is the copyright of the authors who grant Diving and Hyperbaric Medicine a non-exclusive licence to publish the article in electronic and other forms.

Entities:  

Keywords:  Brain; Mucormycosis; Neurosurgery; Refractory infections; Spine

Mesh:

Year:  2021        PMID: 33761547      PMCID: PMC8313776          DOI: 10.28920/dhm51.1.86-93

Source DB:  PubMed          Journal:  Diving Hyperb Med        ISSN: 1833-3516            Impact factor:   0.887


  24 in total

Review 1.  Hyperbaric oxygen therapy: Antimicrobial mechanisms and clinical application for infections.

Authors:  Mohammad Yousef Memar; Mina Yekani; Naser Alizadeh; Hossein Bannazadeh Baghi
Journal:  Biomed Pharmacother       Date:  2018-11-03       Impact factor: 6.529

Review 2.  Hyperbaric oxygen as an adjunctive treatment for zygomycosis.

Authors:  B V John; G Chamilos; D P Kontoyiannis
Journal:  Clin Microbiol Infect       Date:  2005-07       Impact factor: 8.067

Review 3.  Hyperbaric Oxygen Therapy: Side Effects Defined and Quantified.

Authors:  Marvin Heyboer; Deepali Sharma; William Santiago; Norman McCulloch
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-06-01       Impact factor: 4.730

4.  Hyperbaric oxygen therapy in spontaneous brain abscess patients: a population-based comparative cohort study.

Authors:  Jiri Bartek; Asgeir S Jakola; Simon Skyrman; Petter Förander; Peter Alpkvist; Gaston Schechtmann; Martin Glimåker; Agneta Larsson; Folke Lind; Tiit Mathiesen
Journal:  Acta Neurochir (Wien)       Date:  2016-04-25       Impact factor: 2.216

Review 5.  Hyperbaric-oxygen therapy.

Authors:  P M Tibbles; J S Edelsberg
Journal:  N Engl J Med       Date:  1996-06-20       Impact factor: 91.245

6.  Early hyperbaric oxygen therapy improves survival in a model of severe sepsis.

Authors:  Jonathan L Halbach; James M Prieto; Andrew W Wang; Dennis Hawisher; David M Cauvi; Tony Reyes; Jonathan Okerblom; Israel Ramirez-Sanchez; Francisco Villarreal; Hemal H Patel; Stephen W Bickler; George A Perdrizet; Antonio De Maio
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-05-15       Impact factor: 3.619

Review 7.  [Hyperbaric medicine].

Authors:  Tiago D F Fernandes
Journal:  Acta Med Port       Date:  2009-08-10

8.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

Review 9.  Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis.

Authors:  A Tragiannidis; A H Groll
Journal:  Clin Microbiol Infect       Date:  2009-10       Impact factor: 8.067

Review 10.  Therapy of Mucormycosis.

Authors:  Nikolaos V Sipsas; Maria N Gamaletsou; Amalia Anastasopoulou; Dimitrios P Kontoyiannis
Journal:  J Fungi (Basel)       Date:  2018-07-31
View more
  1 in total

Review 1.  COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis.

Authors:  Rachel Samson; Mahesh Dharne
Journal:  3 Biotech       Date:  2021-12-06       Impact factor: 2.893

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.